Restricted accessReview articleFirst published online 2012-2
The Canadian Network for Mood and Anxiety Treatments (Canmat) Task Force Recommendations for the Management of Patients with Mood Disorders and Comorbid Anxiety Disorders
Comorbid mood and anxiety disorders are commonly seen in clinical practice. The goal of this article is to review the available literature on the epidemiologic, etiologic, clinical, and management aspects of this comorbidity and formulate a set of evidence- and consensus-based recommendations. This article is part of a set of Canadian Network for Mood and Anxiety Treatments (CANMAT) Comorbidity Task Force papers.
Methods
We conducted a PubMed search of all English-language articles published between January 1966 and November 2010. The search terms were bipolar disorder and major depressive disorder, cross-referenced with anxiety disorders/symptoms, panic disorder, agoraphobia, generalized anxiety disorder, social phobia, obsessive-compulsive disorder, and posttraumatic stress disorder. Levels of evidence for specific interventions were assigned based on a priori determined criteria, and recommendations were developed by integrating the level of evidence and clinical opinion of the authors.
Results
Comorbid anxiety symptoms and disorders have a significant impact on the clinical presentation and treatment approach for patients with mood disorders. A set of recommendations are provided for the management of bipolar disorder (BD) with comorbid anxiety and major depressive disorder (MDD) with comorbid anxiety with a focus on comorbid posttraumatic stress disorder, use of cognitive-behavioral therapy across mood and anxiety disorders, and youth with mood and anxiety disorders.
Conclusions
Careful attention should be given to correctly identifying anxiety comorbidities in patients with BD or MDD. Consideration of evidence- or consensus-based treatment recommendations for the management of both mood and anxiety symptoms is warranted.
KennedySH, LamRW, ParikhSV, . Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord.2009;117:S1–S2.
2.
YathamLN, KennedySH, SchafferA, . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11:225–255.
3.
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, third edition.Arlington, VA: American Psychiatric Publishing Inc.; 2010.
4.
RakofskyJJ, DunlopBW.Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review. J Clin Psychiatry. 2011;72:81–90.
5.
KeckPEJr, StrawnJR, McElroySL.Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry. 2006;67:(suppl 1)8–15.
6.
FreemanMP, FreemanSA, McElroySL.The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord. 2002;68:1–23.
7.
MerikangasKR, AkiskalHS, AngstJ, . Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–552.
8.
SchafferA, CairneyJ, CheungA, . Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry. 2006;51:9–16.
9.
GoldsteinBI, LevittAJ.The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder. Bipolar Disord. 2008;10:67–78.
10.
BoylanKR, BielingPJ, MarriottM, . Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry. 2004;65:1106–1113.
11.
FeskeU, FrankE, MallingerAG, . Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry. 2000;157:956–962.
12.
OttoMW, SimonNM, WisniewskiSR, . Prospective 12-month course of bipolar disorder in outpatients with and without comorbid anxiety disorders. Br J Psychiatry. 2006;189:20–25.
13.
HenryC, van den BulkeD, BellivierF, . Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry. 2003;64:331–335.
14.
NakagawaA, GrunebaumMF, SullivanGM, . Comorbid anxiety in bipolar disorder: does it have an independent effect on suicidality?Bipolar Disord. 2008;10:530–538.
15.
LevanderE, FryeMA, McElroyS, . Alcoholism and anxiety in bipolar illness: differential lifetime anxiety comorbidity in bipolar I women with and without alcoholism. J Affect Disord. 2007;101:211–217.
16.
AzorinJM, KaladjianA, AdidaM, . Psychopathological correlates of lifetime anxiety comorbidity in bipolar I patients: findings from a French national cohort. Psychopathology. 2009;42:380–386.
17.
AltshulerLL, KupkaRW, HellemannG, . Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network. Am J Psychiatry. 2010;167:708–715.
18.
Nery-FernandesF, QuarantiniLC, Galvão- De-AlmeidaA, . Lower rates of comorbidities in euthymic bipolar patients. World J Biol Psychiatry. 2009;10:474–479.
19.
GaoK, TolliverBK, KempDE, . Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. J Affect Disord. 2008;110:167–173.
20.
SchafferA, CairneyJ, VeldhuizenS, . Comparison of antidepressant use between subjects with bipolar disorder and major depressive disorder with or without comorbid anxiety. J Clin Psychiatry. 2007;68:1785–1792.
21.
El-MallakhRS, HollifieldM.Comorbid anxiety in bipolar disorder alters treatment and prognosis. Psychiatr Q. 2008;79:139–150.
22.
LeeJH, DunnerDL.The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders. Depress Anxiety. 2008;25:91–97.
23.
AlbertU, RossoG, MainaG, . Impact of anxiety disorder comorbidity on quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes. J Affect Disord. 2008;105:297–303.
24.
Kauer-Sant'AnnaM, FreyBN, AndreazzaAC, . Anxiety comorbidity and quality of life in bipolar disorder patients. Can J Psychiatry. 2007;52:175–181.
25.
PerlisRH, MiyaharaS, MarangellLB, . Longterm implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2004;55:875–881.
26.
PerlisRH, OstacherMJ, MiklowitzDJ, . Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry. 2010;71:296–303.
27.
CoryellW, SolomonDA, FiedorowiczJG, . Anxiety and outcome in bipolar disorder. Am J Psychiatry. 2009;166:1238–1243.
28.
WatsonHJ, SwanA, NathanPR.Psychiatric diagnosis and quality of life: the additional burden of psychiatric comorbidity. Compr Psychiatry. 2011;52:265–272. -
29.
Ibilo?luAO, CayköylüA.Distinctive sociodemographic, clinical and temperament characteristics of bipolar-I, bipolar-II and major depressive disorders. Turk Psikiyatri Derg. 2011;22:159–165.
30.
SimonNM, PollackMH, OstacherMJ, . Understanding the link between anxiety symptoms and suicidal ideation and behaviors in outpatients with bipolar disorder. J Affect Disord. 2007;97:91–99.
31.
SimonNM, OttoMW, WisniewskiSR, . Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161:2222–2229.
32.
FagioliniA, FrankE, RucciP, . Mood and anxiety spectrum as a means to identify clinically relevant subtypes of bipolar I disorder. Bipolar Disord. 2007;9:462–467.
33.
AkiskalHS, AkiskalKK, PerugiG, . Bipolar II and anxious reactive “comorbidity”: toward better phenotypic characterization suitable for genotyping. J Affect Disord. 2006;96:239–247.
34.
FawcettJ.DSM-V perspectives on classification of bipolar disorders. In: YathamLN, MajM, eds. Bipolar disorder: clinical and neurobiological foundations.Hoboken, NJ: Wiley Blackwell; 2010:44–51.
35.
PerugiG, AkiskalHS, ToniC, . The temporal relationship between anxiety disorders and (hypo) mania: a retrospective examination of 63 panic, social phobic and obsessive-compulsive patients with comorbid bipolar disorder. J Affect Disord. 2001;67:199–206.
36.
DuffyA, AldaM, HajekT, . Early stages in the development of bipolar disorder. J Affect Disord. 2010;121:127–135.
37.
DilsaverSC, BenazziF, AkiskalKK, . Differential patterns of lifetime multiple anxiety disorder comorbidity between Latino adults with bipolar I and major depressive disorders. Bull Menninger Clin. 2008;72:130–148.
38.
BauerM, BermanSM, SchlagenhaufF, . Regional cerebral glucose metabolism and anxiety symptoms in bipolar depression: effects of levothyroxine. Psychiatry Res. 2010;181:71–76.
39.
OsuchEA, KetterTA, KimbrellTA, . Regional cerebral metabolism associated with anxiety symptoms in affective disorder patients. Biol Psychiatry. 2000;48:1020–1023.
40.
GaudianoBA, MillerIW.Anxiety disorder comorbidity in bipolar I disorder: relationship to depression severity and treatment outcome. Depress Anxiety. 2005;21:71–77.
41.
MainaG, AlbertU, RossoG, . Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry. 2008;69:609–616.
42.
SheehanDV, McElroySL, Harnett-SheehanK, . Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord. 2009;115:376–385.
43.
HirschfeldRM, WeislerRH, RainesSR, . Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67:355–362.
44.
McElroySL, WeislerRH, ChangW, . A doubleblind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71:163–174.
45.
YoungAH, McElroySL, BauerM, . A doubleblind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71:150–162.
46.
TohenM, CalabreseJ, VietaE, . Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007;104:137–146.
47.
SagmanD, LeeB, ChandresenaR, . Canadian A naturalistic study of a community-based cohort treated for bipolar disorder. BMC Psychiatry. 2010;10:24.
48.
PerugiG, ToniC, FrareF, . Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?J Clin Psychopharmacol. 2002;22:584–591.
49.
DavisLL, BartolucciA, PettyF.Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005;85:259–266.
50.
CalabreseJR, DelucchiGA.Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry. 1990;147:431–434.
VietaE, CruzN, Garcia-CampayoJ, . A doubleblind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol. 2008;11:445–452.
53.
PassmoreMJ, GarnhamJ, DuffyA, . Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord. 2003;5:110–114.
LeverichGS, AltshulerLL, FryeMA, . Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163:232–239.
56.
GijsmanHJ, GeddesJR, RendellJM, . Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537–1547.
57.
SachsGS, NierenbergAA, CalabreseJR, . Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711–1722.
58.
SimonNM, OttoMW, WeissRD, . Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004;24:512–520.
59.
ChenYW, DilsaverSC.Comorbidity of panic disorder in bipolar illness: evidence from the Epidemiologic Catchment Area Survey. Am J Psychiatry. 1995;152:280–282.
60.
MagalhaesPVKapczinskiNS, KapczinskiF.Correlates and impact of obsessive-compulsive comorbidity in bipolar disorder. Compr Psychiatry. 2010;51:353–356.
61.
KoyuncuA, TükelR, OzyildirimI, . Impact of obsessive-compulsive disorder comorbidity on the sociodemographic and clinical features of patients with bipolar disorder. Compr Psychiatry. 2010;51:293–297.
McElroySL, AltshulerLL, SuppesT, . Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry. 2001;158:420–426.
64.
KrügerS, CookeRG, HaseyGM, . Comorbidity of obsessive compulsive disorder in bipolar disorder. J Affect Disord. 1995;34:117–120.
65.
KrügerS, BräunigP, CookeRG.Comorbidity of obsessive-compulsive disorder in recovered inpatients with bipolar disorder. Bipolar Disord. 2000;2:71–74.
66.
RuscioAM, SteinDJ, ChiuWT, . The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15:53–63.
67.
PashinianA, FaragianS, LeviA, . Obsessivecompulsive disorder in bipolar disorder patients with first manic episode. J Affect Disord. 2006;94:151–156.
68.
IsslerCK, AmaralJA, TamadaRS, . Clinical expression of obsessive-compulsive disorder in women with bipolar disorder. Rev Bras Psiquiatr. 2005;27:139–142.
69.
BaldessariniRJ, PerryR, PikeJ.Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23:95–105.
70.
PerugiG, AkiskalHS, PfannerC, . The clinical impact of bipolar and unipolar affective comorbidity on obsessive-compulsive disorder. J Affect Disord. 1997;46:15–23.
71.
RajaM, AzzoniA.Clinical management of obsessive-compulsive-bipolar comorbidity: a case series. Bipolar Disord. 2004;6:264–270.
72.
BisolLW, LaraDR.Improvement of obsessive-compulsive disorder with divalproex and lamotrigine in two patients with bipolar II disorder. Pharmacopsychiatry. 2009;42:37–39.
73.
MarazzitiD, PfannerC, Dell'OssoB, . Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol. 2005;19:392–394.
74.
PetrikisP, AndreouC, BozikasVP, . Effective use of olanzapine for obsessive-compulsive symptoms in a patient with bipolar disorder. Can J Psychiatry. 2004;49:572–573.
75.
JacobsenFM.Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry. 1995;56:423–429.
76.
PfannerC, MarazzitiD, Dell'OssoL, . Risperidone augmentation in refractory obsessivecompulsive disorder: an open-label study. Int Clin Psychopharmacol. 2000;15:297–301.
77.
GaoK, MuzinaD, GajwaniP, . Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67:1327–1340.
78.
UguzF.Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder. Gen Hosp Psychiatry. 2010;32:556–558.
79.
PerugiG, ToniC, FrareF, . Obsessivecompulsive-bipolar comorbidity: a systematic exploration of clinical features and treatment outcome. J Clin Psychiatry. 2002;63:1129–1134.
80.
MasiG, ToniC, PerugiG, . Anxiety disorders in children and adolescents with bipolar disorder: a neglected comorbidity. Can J Psychiatry. 2001;46:797–802.
81.
MacKinnonDF, ZandiPP, CooperJ, . Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry. 2002;159:30–35.
82.
GoodwinRD, HovenCW.Bipolar-panic comorbidity in the general population: prevalence and associated morbidity. J Affect Disord. 2002;70:27–33.
83.
FortyL, SmithD, JonesL, . Clinical characteristics of unipolar disorder and bipolar disorder according to the lifetime presence of recurrent panic attacks. Bipolar Disord. 2009;11:307–315.
84.
FrankE, CyranowskiJM, RucciP, . Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry. 2002;59:905–911.
85.
MacKinnonDF, ZandiPP, GershonES, . Association of rapid mood switching with panic disorder and familial panic risk in familial bipolar disorder. Am J Psychiatry. 2003;160:1696–1698.
86.
TonioloRA, CaetanoSC, da SilvaPV, . Clinical significance of lifetime panic disorder in the course of bipolar disorder type I. Compr Psychiatry. 2009;50:9–12.
87.
MulaM, PiniS, MonteleoneP, . Different temperament and character dimensions correlate with panic disorder comorbidity in bipolar disorder and unipolar depression. J Anxiety Disord. 2008;22:1421–1426.
88.
DilsaverSC, ChenYW.Social phobia, panic disorder and suicidality in subjects with pure and depressive mania. J Affect Disord. 2003;77:173–177.
89.
KilbaneEJ, GokbayrakNS, GalynkerI, . A review of panic and suicide in bipolar disorder: does comorbidity increase risk?J Affect Disord. 2009;115:1–10.
90.
RotondoA, MazzantiC, Dell'OssoL, . Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry. 2002;159:23–29.
91.
ChengR, JuoSH, LothJE, . Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry. 2006;11:252–260.
92.
DoughtyCJ, WellsJE, JoycePR, . Bipolar-panic disorder comorbidity within bipolar disorder families: a study of siblings. Bipolar Disord. 2004;6:245–252.
93.
MacKinnonDF, ZamoiskiR.Panic comorbidity with bipolar disorder: what is the manic-panic connection? Bipolar Disord. 2006;8:648–664.
94.
MacKinnonDF, CraigheadB, Hoehn-SaricR.Carbon dioxide provocation of anxiety and respiratory response in bipolar disorder. J Affect Disord. 2007;99:45–49.
95.
SimonNM, OttoMW, FischmannD, . Panic disorder and bipolar disorder: anxiety sensitivity as a potential mediator of panic during manic states. J Affect Disord. 2005;87:101–105.
96.
PerugiG, FrareF, ToniC, . Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year “open” follow-up study. Eur Arch Psychiatry Clin Neurosci. 2010;260:553–560.
97.
BaetzM, BowenRC.Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry. 1998;43:73–77.
98.
SepedeG, GambiF, OnofrjM, . Olanzapine enhances anxiety response to an SSRI in a woman with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:303–304.
99.
OttoMW, PerlmanCA, WernickeR, . Posttraumatic stress disorder in patients with bipolar disorder: a review of prevalence, correlates, and treatment strategies. Bipolar Disord. 2004;6:470–479.
100.
BaldassanoCF, MarangellLB, GyulaiL, . Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. Bipolar Disord. 2005;7:465–470.
101.
KennedyBL, DhaliwalN, PedleyL, . Posttraumatic stress disorder in subjects with schizophrenia and bipolar disorder. J Ky Med Assoc. 2002;100:395–399.
102.
BrownGR, McBrideL, BauerMS, . Impact of childhood abuse on the course of bipolar disorder: a replication study in U. S. veterans. J Affect Disord. 2005;89:57–67.
103.
RomeroS, BirmaherB, AxelsonD, . Prevalence and correlates of physical and sexual abuse in children and adolescents with bipolar disorder. J Affect Disord. 2009;112:144–150.
104.
GoldsteinTR, BirmaherB, AxelsonD, . History of suicide attempts in pediatric bipolar disorder: factors associated with increased risk. Bipolar Disord. 2005;7:525–535.
105.
LeverichGS, McElroySL, SuppesT, . Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry. 2002;51:288–297.
106.
NeriaY, BrometEJ, SieversS, . Trauma exposure and posttraumatic stress disorder in psychosis: findings from a first-admission cohort. J Consult Clin Psychol. 2002;70:246–251.
107.
AxelsonD, BirmaherB, StroberM, . Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry. 2006;63:1139–1148.
108.
FindlingRL, GraciousBL, McNamaraNK, . Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord. 2001;3:202–210.
109.
BiedermanJ, FaraoneSV, WozniakJ, . Clinical correlates of bipolar disorder in a large, referred sample of children and adolescents. J Psychiatr Res. 2005;39:611–622.
110.
GellerB, TillmanR, CraneyJL, . Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch Gen Psychiatry. 2004;61:459–467.
111.
DicksteinDP, RichBA, BinstockAB, . Comorbid anxiety in phenotypes of pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2005;15:534–548.
112.
SalaR, AxelsonDA, Castro-FornielesJ, . Comorbid anxiety in children and adolescents with bipolar spectrum disorders: prevalence and clinical correlates. J Clin Psychiatry. 2010;71:1344–1350.
113.
BrotmanMA, RichBA, SchmajukM, . Attention bias to threat faces in children with bipolar disorder and comorbid lifetime anxiety disorders. Biol Psychiatry. 2007;61:819–821.
114.
SimeonovaDI, JacksonV, AttallaA, . Subcortical volumetric correlates of anxiety in familial pediatric bipolar disorder: a preliminary investigation. Psychiatry Res. 2009;173:113–120.
115.
DelBelloMP, HansemanD, AdlerCM, . Twelvemonth outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am J Psychiatry. 2007;164:582–590.
116.
JoshiG, MickE, WozniakJ, . Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder. Bipolar Disord. 2010;12:196–204.
117.
MasiG, PerugiG, MillepiediS, . Pharmacological response in juvenile bipolar disorder subtypes: a naturalistic retrospective examination. Psychiatry Res. 2010;177:(1-2)192–198.
118.
MasiG, PerugiG, ToniC, . Obsessivecompulsive bipolar comorbidity: focus on children and adolescents. J Affect Disord. 2004;78:175–183.
119.
FaeddaGL, BaldessariniRJ, GlovinskyIP, . Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J Affect Disord. 2004;82:149–158.
120.
KowatchRA, FristadM, BirmaherB, . Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:213–235.
121.
GoldsteinBI, LevittAJ.Prevalence and correlates of bipolar I disorder among adults with primary youth-onset anxiety disorders. J Affect Disord. 2007;103:187–195.
122.
GoldsteinBI, ShamseddeenW, AxelsonDA, . Clinical, demographic, and familial correlates of bipolar spectrum disorders among offspring of parents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2010;49:388–396.
123.
WalkupJT, AlbanoAM, PiacentiniJ, . Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359:2753–2766.
124.
WozniakJ, BiedermanJ, MonuteauxMC, . Parsing the comorbidity between bipolar disorder and anxiety disorders: a familial risk analysis. J Child Adolesc Psychopharmacol. 2002;12:101–111.
125.
KesslerRC, GruberM, HettemaJM, . Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med. 2008;38:365–374.
126.
PattenSB, Gordon-BrownL, MeadowsG.Simulation studies of age-specific lifetime major depression prevalence. BMC Psychiatry. 2010;10:85.
127.
AndradeL, Caraveo-AnduagaJJ, BerglundP, . The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003;12:3–21.
128.
GwynnRC, McQuistionHL, McVeighKH, . Prevalence, diagnosis, and treatment of depression and generalized anxiety disorder in a diverse urban community. Psychiatr Serv. 2008;59:641–647.
129.
KellerMB, LavoriPW, WunderJ, . Chronic course of anxiety disorders in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1992;31:595–599.
130.
KellerMB.Prevalence and impact of comorbid anxiety and bipolar disorder. J Clin Psychiatry. 2006;67:5–7.
131.
PiccinelliM, WilkinsonG.Outcome of depression in psychiatric settings. Br J Psychiatry. 1994;164:297–304.
132.
PollackMH, OttoMW.Long-term course and outcome of panic disorder. J Clin Psychiatry. 1997;58:57–60.
133.
SpijkerJ, de GraafR, BijlRV, . Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry. 2002;181:208–213.
134.
VollrathM, AngstJ.Outcome of panic and depression in a seven-year follow-up: results of the Zurich study. Acta Psychiatr Scand. 1989;80:591–596.
135.
BijlRV, RavelliA.Current and residual functional disability associated with psychopathology: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol Med. 2000;30:657–668.
136.
HechtH, von ZerssenD, WittchenHU.Anxiety and depression in a community sample: the influence of comorbidity on social functioning. J Affect Disord. 1990;18:137–144.
137.
Roy-ByrnePP, StangP, WittchenHU, . Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry. 2000;176:229–235.
138.
BruceSE, YonkersKA, OttoMW, . Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005;162:1179–1187.
139.
BrownC, SchulbergHC, MadoniaMJ, . Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry. 1996;153:1293–1300.
140.
NinanPT, BergerJ.Symptomatic and syndromal anxiety and depression. Depress Anxiety. 2001;14:79–85.
141.
FavaM, RushAJ, AlpertJE, . Difference in treatment outcome in outpatients with anxious versus non- anxious depression: a STAR*D report. Am J Psychiatry. 2008;165:342–351.
142.
SonawallaSB, SpillmannMK, KolskyAR, . Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry. 1999;60:580–583.
143.
Hoehn-SaricR, NinanP, BlackDW, . Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000;57:76–82.
144.
FavaM, RosenbaumJF, HoogSL, . Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord. 2000;59:119–126.
145.
RussellJM, KoranLM, RushJ, . Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety. 2001;13:18–27.
146.
TollefsonGD, HolmanSL, SaylerME, . Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55:50–59.
147.
PanzerMJ.Are SSRIs really more effective for anxious depression? Ann Clin Psychiatry. 2005;17:23–29.
148.
LamRW, KennedySH, GrigoriadisS, . Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117:S26–S43.
149.
LepolaU, AratoM, ZhuY, . Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry. 2003;64:654–662.
150.
Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006;51:9S-91S.
151.
BreslauN, DavisGC, AndreskiP, . Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry. 1991;48:216–222.
152.
CreamerM, BurgessP, McFarlaneAC.Posttraumatic stress disorder: findings from the Australian National Survey of Mental Health and Well-being. Psychol Med. 2001;31:1237–1247.
153.
KeaneTM, KaloupekDG.Comorbid psychiatric disorders in PTSD. Implications for research. Ann N Acad Y Sci. 1997;821:24–34.
154.
ForbesD, CreamerM, HawthorneG, . Comorbidity as a predictor of symptom change after treatment in combat-related posttraumatic stress disorder. J Nerv Ment Dis. 2003;191:93–99.
155.
GradusJL, QinP, LincolnAK, . Posttraumatic stress disorder and completed suicide. Am J Epidemiol. 2010;171:721–727.
156.
KesslerRC, SonnegaA, BrometE, . Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52:1048–1060.
157.
GinzburgK.Comorbidity of PTSD and depression following myocardial infarction. J Affect Disord. 2006;94:135–143.
158.
MollicaRF, McInnesK, Sarajli?N, . Disability associated with psychiatric comorbidity and health status in Bosnian refugees living in Croatia. JAMA. 1999;282:433–439.
159.
SalciogluE, BasogluM, LivanouM.Long-term psychological outcome for non-treatment-seeking earthquake survivors in Turkey. J Nerv Ment Dis. 2003;191:154–160.
160.
SundquistK, JohanssonLM, DeMarinisV, . Posttraumatic stress disorder and psychiatric co-morbidity: symptoms in a random sample of female Bosnian refugees. Eur Psychiatry. 2005;20:158–164.
161.
HashemianF, KhoshnoodK, DesaiMM, . Anxiety, depression, and posttraumatic stress in Iranian survivors of chemical warfare. JAMA. 2006;296:560–566.
162.
ZayfertC, BeckerCB, UngerDL, . Comorbid anxiety disorders in civilians seeking treatment for posttraumatic stress disorder. J Trauma Stress. 2002;15:31–38.
163.
MayouR, BryantB, EhlersA.Prediction of psychological outcomes one year after a motor vehicle accident. Am J Psychiatry. 2001;158:1231–1238.
164.
McFarlaneAC, PapayP.Multiple diagnoses in posttraumatic stress disorder in the victims of a natural disaster. J Nerv Ment Dis. 1992;180:498–504.
165.
BradyKT, ClaryCM.Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Compr Psychiatry. 2003;44:360–369.
166.
GinzburgK, Ein-DorT, SolomonZ.Comorbidity of posttraumatic stress disorder, anxiety and depression: a 20-year longitudinal study of war veterans. J Affect Disord. 2010;123:249–257.
167.
MaesM, MylleJ, DelmeireL, . Psychiatric morbidity and comorbidity following accidental man-made traumatic events: incidence and risk factors. Eur Arch Psychiatry Clin Neurosci. 2000;250:156–162.
168.
MomartinS, SiloveD, ManicavasagarV, . Comorbidity of PTSD and depression: associations with trauma exposure, symptom severity and functional impairment in Bosnian refugees resettled in Australia. J Affect Disord. 2004;80:231–238.
169.
WoodwardSH, FriedmanMJ, BliwiseDL.Sleep and depression in combat-related PTSD inpatients. Biol Psychiatry. 1996;39:182–192.
170.
MerikangasKR, AmesM, CuiL, . The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry. 2007;64:1180–1188.
171.
SareenJ, HoulahanT, CoxBJ, . Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis. 2005;193:450–454.
172.
SareenJ, CoxBJ, SteinMB, . Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample. Psychosom Med. 2007;69:242–248.
173.
OquendoMA, FriendJM, HalberstamB, . Association of comorbid posttraumatic stress disorder and major depression with greater risk for suicidal behavior. Am J Psychiatry. 2003;160:580–582.
174.
SouthwickSM, VythilingamM, CharneyDS.The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu Rev Clin Psychol. 2005;1:255–291.
175.
AiranRD, MeltzerLA, RoyM, . High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science. 2007; 317:819–823.
176.
DavidDJ, SamuelsBA, RainerQ, . Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron. 2009;62:479–493.
177.
BanasrM, DumanRS.Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. CNS Neurol Disord Drug Targets. 2007;6:311–320.
178.
FeldmannREJr, SawaA, SeidlerGH.Causality of stem cell based neurogenesis and depression—to be or not to be, is that the question?J Psychiatr Res.2007;41:713–723.
179.
PereraTD, ParkS, NemirovskayaY.Cognitive role of neurogenesis in depression and antidepressant treatment. Neuroscientist. 2008;14:326–338.
180.
SchloesserRJ, ManjiHK, MartinowichK.Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response. Neuroreport. 2009;20:553–557.
181.
ThomasRM, PetersonDA.Even neural stem cells get the blues: evidence for a molecular link between modulation of adult neurogenesis and depression. Gene Expr. 2008;14:183–193.
182.
VollmayrB, MahlstedtMM, HennFA.Neurogenesis and depression: what animal models tell us about the link. Eur Arch Psychiatry Clin Neurosci. 2007;257:300–303.
183.
WangJW, DavidDJ, MoncktonJE, . Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008;28:1374–1384.
184.
SahayA, HenR.Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007;10:1110–1115.
185.
DeCarolisNA, EischAJ.Hippocampal neurogenesis as a target for the treatment of mental illness: a critical evaluation. Neuropharmacology. 2010;58:884–893.
186.
KitayamaN, VaccarinoV, KutnerM, . Magnetic resonance imaging (MRI) measurement of hippocampal volume in posttraumatic stress disorder: a meta-analysis. J Affect Disord. 2005;88:79–86.
187.
WignallEL, DicksonJM, VaughanP, . Smaller hippocampal volume in patients with recentonset posttraumatic stress disorder. Biol Psychiatry. 2004;56:832–836.
188.
BonneO, BrandesD, GilboaA, . Longitudinal MRI study of hippocampal volume in trauma survivors with PTSD. Am J Psychiatry. 2001;158:1248–1251.
189.
Fennema-NotestineC, SteinMB, KennedyCM, . Brain morphometry in female victims of intimate partner violence with and without posttraumatic stress disorder. Biol Psychiatry. 2002;52:1089–1101.
190.
CarrionVG, WeemsCF, EliezS, . Attenuation of frontal asymmetry in pediatric posttraumatic stress disorder. Biol Psychiatry. 2001;50:943–951.
191.
De BellisMD, HallJ, BoringAM, . A pilot longitudinal study of hippocampal volumes in pediatric maltreatment-related posttraumatic stress disorder. Biol Psychiatry. 2001;50:305–309.
192.
BremnerJD, NarayanM, StaibLH, . Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry. 1999;156:1787–1795.
193.
BremnerJD, VythilingamM, VermettenE, . Neural correlates of declarative memory for emotionally valenced words in women with posttraumatic stress disorder related to early childhood sexual abuse. Biol Psychiatry. 2003;53:879–889.
194.
ShinLM, ShinPS, HeckersS, . Hippocampal function in posttraumatic stress disorder. Hippocampus. 2004;14:292–300.
195.
BergerW, MendlowiczMV, Marques-PortellaC, . Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:169–180.
SteinDJ, IpserJC, SeedatS.Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006:CD002795.
198.
DavidsonJ, BaldwinD, SteinDJ, . Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006;63:1158–1165.
199.
WalderhaugE, KassermanS, AikinsD, . Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder. Pharmacopsychiatry. 2010;43:45–49.
200.
MargoobMA, AliZ, AndradeC.Efficacy of ECT in chronic, severe, antidepressant- and CBT-refractory PTSD: an open, prospective study. Brain Stimul. 2010;3:28–35.
201.
BallengerJC, DavidsonJR, LecrubierY, . Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 2004;65:55–62.
202.
MarshallRD, PierceD.Implications of recent findings in posttraumatic stress disorder and the role of pharmacotherapy. Harv Rev Psychiatry. 2000;7:247–256.
203.
HetrickSE, PurcellR, GarnerB, . Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2010:CD007316.
204.
ParikhSV, SegalZV, GrigoriadisS, . Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord. 2009;117:S15–S25.
205.
MitteK.Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull. 2005;131:785–795.
206.
RiefW, TrenkampS, AuerC, . Cognitive behavior therapy in panic disorder and comorbid major depression. A naturalistic study. Psychother Psychosom. 2000;69:70–78.
207.
van BalkomAJ, van BoeijenCA, BoekeAJ, . Comorbid depression, but not comorbid anxiety disorders, predicts poor outcome in anxiety disorders. Depress Anxiety. 2008;25:408–415.
208.
HofmannSG, SmitsJA.Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008;69:621–632.
209.
ChamblessDL, TranGQ, GlassCR.Predictors of response to cognitive-behavioral group therapy for social phobia. J Anxiety Disord. 1997;11:221–240.
210.
AcarturkC, CuijpersP, van StratenA, . Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med. 2009;39:241–254.
211.
MoscovitchDA, HofmannSG, SuvakMK, . Mediation of changes in anxiety and depression during treatment of social phobia. J Consult Clin Psychol. 2005;73:945–952.
212.
SteketeeG, ChamblessDL, TranGQ.Effects of axis I and II comorbidity on behavior therapy outcome for obsessive-compulsive disorder and agoraphobia. Compr Psychiatry. 2001;42:76–86.
213.
OverbeekT, SchruersK, VermettenE, . Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J Clin Psychiatry. 2002;63:1106–1112.
214.
BrentD, EmslieG, ClarkeG, . Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008;299:901–913.
215.
MarchJ, SilvaS, PetryckiS, . Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807–820.
216.
GoodyerI, DubickaB, WilkinsonP, . Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ. 2007;335:142.
217.
KovacsM, GatsonisC, PaulauskasSL, . Depressive disorders in childhood. IV. A longitudinal study of comorbidity with and risk for anxiety disorders. Arch Gen Psychiatry. 1989;46:776–782.
218.
LewinsohnPM, ClarkeGN, SeeleyJR, . Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry. 1994;33:809–818.
219.
RaoU, RyanND, BirmaherB, . Unipolar depression in adolescents: clinical outcome in adulthood. J Am Acad Child Adolesc Psychiatry. 1995;34:566–578.
220.
SanfordM, SzatmariP, SpinnerM, . Predicting the one-year course of adolescent major depression. J Am Acad Child Adolesc Psychiatry. 1995;34:1618–1628.
221.
GouldMS, GreenbergT, VeltingDM, . Youth suicide risk and preventive interventions: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry. 2003;42:386–405.
KendallPC, KortlanderE, ChanskyTE, . Comorbidity of anxiety and depression in youth: treatment implications. J Consult Clin Psychol. 1992;60:869–880.
224.
YoungJF, MufsonL, DaviesM.Impact of comorbid anxiety in an effectiveness study of interpersonal psychotherapy for depressed adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:904–912.
225.
BrentDA, KolkoDJ, BirmaherB, . Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry. 1998;37:906–914.
226.
RohdeP, ClarkeGN, LewinsohnPM, . Impact of comorbidity on a cognitive-behavioral group treatment for adolescent depression. J Am Acad Child Adolesc Psychiatry. 2001;40:795–802.
227.
CurryJ, RohdeP, SimonsA, . Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45:1427–1439.
228.
EmslieGJ, MayesT, PortaG, . Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry. 2010;167:782–791.
229.
AsarnowJR, EmslieG, ClarkeG, . Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry. 2009;48:330–339.
